China Meheco(SH:600056) Mei Ri Jing Ji Xin Wen·2025-09-09 02:22Core Viewpoint - The Hong Kong stock market is experiencing a strong performance in the innovative drug sector, driven by successful collaborations, positive clinical data, and supportive policies [1] Group 1: Market Performance - The innovative drug sector in Hong Kong saw significant gains, with Rongchang Bio rising over 14%, Junshi Bio and Lepu Biopharma-B increasing over 7%, and Fosun Pharma up over 4% [1] - The Hong Kong Innovative Drug ETF (159567) opened lower but rose by 1.77% during the session [1] Group 2: Sector Drivers - The innovative drug sector's strong performance in the first half of the year is attributed to the successful implementation of BD collaborations, excellent clinical data releases, and supportive government policies [1] - New products are expected to quickly realize commercial value due to the supportive policies for innovative drugs, leading to a rapid increase in the market share of domestic innovative drugs in hospitals [1] Group 3: Industry Outlook - The mid-year performance reports indicate a recovery in earnings for segments such as innovative drugs, CXO, and biopharmaceuticals, showcasing the global competitiveness of China's pharmaceutical industry [1] - The long-term outlook for the pharmaceutical industry is positive, with expectations for the emergence of global large companies [1] Group 4: Investment Opportunities - The Hong Kong Innovative Drug ETF (159567) tracks the Guozheng Hong Kong Stock Connect Innovative Drug Index, reflecting the performance characteristics of listed companies in the innovative drug sector within the Stock Connect framework [1] - Investors can also access the Hong Kong Innovative Drug ETF feeder funds (Class A: 023929; Class C: 023930) for easy exposure to the upward opportunities in the innovative drug sector [1]